Phase 1b/2 study of pembrolizumab plus lenvatinib or pembrolizumab coformulated with vibostolimab in participants (pts) with metastatic neuroendocrine prostate cancer (NEPC): KEYNOTE-365 cohorts F and H.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Gunhild Von Amsberg, Martin Boegemann, Johann S. De Bono, Niven Mehra, Howard Gurney, Josep M. Piulats, Alexandra Drakaki, Debbie GJ Robbrecht, Mariusz Kwiatkowski, Elizabeth R. Kessler, Urban Emmenegger, Cagatay Arslan, Gedske Daugaard, Enrique Castellanos, Christopher Eing Wee, Lockman Bousserouel, Charles Schloss, Kentaro Imai, Evan Y. Yu
Institutions: University Medical Center Hamburg-Eppendorf, Martini-Klinik, University Hospital Münster, Institute of Cancer Research, Royal Marsden Hospital, Radboud University Medical Center, Macquarie University, Institut Català d'Oncologia, University of California, Los Angeles, Los Angeles Medical Center, Erasmus MC Cancer Institute, University of Colorado Cancer Center, Sunnybrook Hospital, Sunnybrook Research Institute, İzmir University of Economics, Copenhagen University Hospital, Rigshospitalet, Karolinska University Hospital, Cleveland Clinic, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Washington, Fred Hutch Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162499537
Cites:
Cited by:
Related to: